NTLA Q4 2024 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+771.6% YoY

Gross Profit

$13M100.0% margin

Operating Income

-$136M-1059.9% margin

Net Income

-$129M-1001.2% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+41.3%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$86M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$319M

Stockholders' Equity

$872M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	-$2M	+771.6%
Gross Profit	$13M	-$4M	+393.7%
Operating Income	-$136M	-$140M	+2.5%
Net Income	-$129M	-$132M	+2.5%